Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04975906
Other study ID # SingHealth CIRB: 2019/2463
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2017
Est. completion date June 6, 2023

Study information

Verified date June 2023
Source Changi General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: The serum anion gap (AG) is commonly used as a screening tool for acid-base disorders. With modern laboratory techniques using ion-selective electrodes to measure the main electrolyte components of the AG, our definition high AG (HAGMA) should be reviewed. Aim: This study aims to assess the diagnostic value of AG and to determine a diagnostic threshold for HAGMA in a high-prevalence clinical setting. Method: Computerized extraction of anonymised data from electronic medical records was performed. A pre-defined criteria included all inpatients of an acute-care hospital who had measurements for organic acids (lactate, ketone or salicylate) paired with a serum urea, electrolyte and creatinine panel.


Description:

BACKGROUND: The urea & electrolyte (U&E) panel is a common blood test that is often performed for any ill patients in a hospital. Evaluation of this panel can reveal serious underlying acid-base disturbances, often a harbinger of further haemodynamic compromise. The detection of a gap acidosis often is the first indicator of a serious underlying condition. The AG is a reflection of the unmeasured anions. The anion gap (AG) is derived from the U&E panel by subtracting measured anions from measured cations: AG = [Sodium] + [Potassium] - [Chloride] - [Bicarbonate] The serum potassium can be included in the calculation, but due to low variability of serum potassium, most clinicians omit serum potassium in the calculation of AG. Accumulation of organic acids (e.g. lactic acid, ketones, uremic toxins) results in a high AG metabolic acidosis (HAGMA) and such patients have a significant risk of further clinical deterioration. It has however been challenging to assess for gap acidosis as the range for normal AG can vary greatly due to historical differences in the laboratory techniques used to measure the constituents of AG as well as a component of interindividual variability. In the past, AG were reported (in milliequivalents per liter, mEq/L) in the range of 9-17 milliequivalents/L or 8-16 milliequivalents/L with older laboratory techniques such as flame photometry, colorimetric method. In more recent years with the advent of use of ion-selective electrodes (ISE), published literature suggests that the AG range may be lower as the ISE may give higher readings of serum chloride. Some clinical texts and laboratories have listed the reference range of AG as 3-11 milliequivalents/L or 5-12 milliequivalents/L. Despite so, the reference range for serum sodium, potassium and chloride themselves have remained the same over the years despite changes in laboratory techniques. With such conflicting information, it is important to re-evaluate the screening or diagnostic threshold of the AG based on modern laboratory techniques. OBJECTIVES: To assess the diagnostic threshold of AG to detect gap acidosis due to organic acidosis. METHODS: Study protocol was reviewed and approved by the institutional ethics committee (SingHealth centralised institutional review board: 2019/2463). A waiver of consent was obtained as data was anonymised. This is a retrospective study. Data will be extracted from electronic medical and laboratory records from all inpatient admissions to an acute hospital. Data extracted will be anonymized. The search criteria will include the following parameters: - all inpatient admissions 2017 - 2020 and - patients with serum lactate, ketones and salicylates performed, and - patients with urea, electrolytes and creatinine at the same time. Data to be extracted include baseline demographic data, admission date, and laboratory results including urea / electrolytes / creatinine, albumin, glucose, calcium, phosphate, magnesium, albumin, liver function test, arterial blood test and hemoglobin. If patients had multiple blood samples taken, only laboratory results from a single sample will be included. This will be selected by an automated algorithm which selects the sample with the most complete information. Statistical Analysis Plan: The patients will be divided into 2 groups - with / without organic acidosis (elevated serum lactate, ketones and/or salicylates). An area under the curve (AUC) of receiver operating characteristics (ROC) analysis of AG for the detection of organic acidosis will be performed. The optimal cut-off threshold will be explored using the Youden index. Analysis of the diagnostic threshold of AG at different cut-off levels will be performed and the performance of the AG as a screening test at different cut-off thresholds will be assessed by reviewing the sensitivity, specificity, positive/negative predictive values and related indicators. A recommended cut-off value will be determined based on a test sensitivity adjudicated to be acceptable.


Recruitment information / eligibility

Status Completed
Enrollment 16475
Est. completion date June 6, 2023
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Admitted from 01 July 2017 to 31 December 2019 - Patients who have had blood lactate, blood ketones and serum salicylates performed during this time period - Patient who also had urea / creatinine and a comprehensive panel of electrolytes performed up to +/-12h of blood lactate, blood ketones and serum salicylates being performed Exclusion Criteria: - Patient who did not have blood lactate, blood ketones and serum salicylates performed during this time period - Patient who did not have urea / creatinine and a comprehensive panel of electrolytes performed up to +/-12h of blood lactate, blood ketones and serum salicylates being performed

Study Design


Locations

Country Name City State
Singapore Changi General Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
Changi General Hospital

Country where clinical trial is conducted

Singapore, 

References & Publications (4)

Ayala-Lopez N, Harb R. Interpreting Anion Gap Values in Adult and Pediatric Patients: Examining the Reference Interval. J Appl Lab Med. 2020 Jan 1;5(1):126-135. doi: 10.1373/jalm.2019.029496. — View Citation

Lolekha PH, Vanavanan S, Lolekha S. Update on value of the anion gap in clinical diagnosis and laboratory evaluation. Clin Chim Acta. 2001 May;307(1-2):33-6. doi: 10.1016/s0009-8981(01)00459-4. — View Citation

Sadjadi SA, Manalo R, Jaipaul N, McMillan J. Ion-selective electrode and anion gap range: What should the anion gap be? Int J Nephrol Renovasc Dis. 2013 Jun 7;6:101-5. doi: 10.2147/IJNRD.S44689. Print 2013. — View Citation

Winter SD, Pearson JR, Gabow PA, Schultz AL, Lepoff RB. The fall of the serum anion gap. Arch Intern Med. 1990 Feb;150(2):311-3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve of Receiver Operating Characteristics An area under the curve (AUC) of receiver operating characteristics (ROC) of Anion Gap for the presence of organic acidosis will be calculated.
An AUC >0.8 suggests that Anion Gap performs well as a test for the presence of organic acidosis.
End of study period, estimated 3 years
Primary An optimal cut-off threshold of Anion Gap The optimal cut-off threshold will be determined. At each cut-off level. the sensitivity and specificity will be calculated. One recommended cut-off value for Anion Gap with a sensitivity >95% will be accepted. End of study period, estimated 3 years
Secondary Subgroup Analysis for Performance of Anion Gap as a screening test for Organic Acidosis The AUC-ROC for Anion Gap will be calculated for each patient subgroup: serum urea (=7.7 mmol/L or >7.7 mmol/L), age (below or above median age), sex, race and concomitant respiratory acid-base disorders (present or absent) End of study period, estimated 3 years
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT03671447 - Enhanced Recovery After Intensive Care (ERIC) N/A
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Completed NCT04239209 - Effect of Intensivist Communication on Surrogate Prognosis Interpretation N/A
Completed NCT05531305 - Longitudinal Changes in Muscle Mass After Intensive Care N/A
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Completed NCT02916004 - The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients. N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Completed NCT04479254 - The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study) N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Recruiting NCT02989051 - Fluid Restriction Keeps Children Dry Phase 2/Phase 3
Completed NCT02899208 - Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients? N/A
Completed NCT03048487 - Protein Consumption in Critically Ill Patients
Recruiting NCT02163109 - Oxygen Consumption in Critical Illness